» Articles » PMID: 20591140

Polycystic Ovary Syndrome: a Complex Condition with Psychological, Reproductive and Metabolic Manifestations That Impacts on Health Across the Lifespan

Overview
Journal BMC Med
Publisher Biomed Central
Specialty General Medicine
Date 2010 Jul 2
PMID 20591140
Citations 457
Authors
Affiliations
Soon will be listed here.
Abstract

Polycystic ovary syndrome (PCOS) is of clinical and public health importance as it is very common, affecting up to one in five women of reproductive age. It has significant and diverse clinical implications including reproductive (infertility, hyperandrogenism, hirsutism), metabolic (insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, adverse cardiovascular risk profiles) and psychological features (increased anxiety, depression and worsened quality of life). Polycystic ovary syndrome is a heterogeneous condition and, as such, clinical and research agendas are broad and involve many disciplines. The phenotype varies widely depending on life stage, genotype, ethnicity and environmental factors including lifestyle and bodyweight. Importantly, PCOS has unique interactions with the ever increasing obesity prevalence worldwide as obesity-induced insulin resistance significantly exacerbates all the features of PCOS. Furthermore, it has clinical implications across the lifespan and is relevant to related family members with an increased risk for metabolic conditions reported in first-degree relatives. Therapy should focus on both the short and long-term reproductive, metabolic and psychological features. Given the aetiological role of insulin resistance and the impact of obesity on both hyperinsulinaemia and hyperandrogenism, multidisciplinary lifestyle improvement aimed at normalising insulin resistance, improving androgen status and aiding weight management is recognised as a crucial initial treatment strategy. Modest weight loss of 5% to 10% of initial body weight has been demonstrated to improve many of the features of PCOS. Management should focus on support, education, addressing psychological factors and strongly emphasising healthy lifestyle with targeted medical therapy as required. Monitoring and management of long-term metabolic complications is also an important part of routine clinical care. Comprehensive evidence-based guidelines are needed to aid early diagnosis, appropriate investigation, regular screening and treatment of this common condition. Whilst reproductive features of PCOS are well recognised and are covered here, this review focuses primarily on the less appreciated cardiometabolic and psychological features of PCOS.

Citing Articles

Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS.

Houston E, Templeman N, Templeman N J Endocrinol. 2025; .

PMID: 40013621 PMC: 11906131. DOI: 10.1530/JOE-24-0269.


Diagnosis and Treatment of Adolescent Polycystic Ovary syndrome:A Review.

Zhang Y, Yang K, Fan T, Zheng D, Liu H Int J Womens Health. 2025; 17:459-474.

PMID: 39995885 PMC: 11847718. DOI: 10.2147/IJWH.S506498.


The role of salivary antioxidant level in polycystic ovary syndrome women under assisted reproductive technology treatment: A case-control study.

Gholizadeh N, Koopaie M, Aleyasin A, Milani A, Aghahosseini M, Kharrazifard M Int J Reprod Biomed. 2025; 22(12):975-984.

PMID: 39968368 PMC: 11830924. DOI: 10.18502/ijrm.v22i12.18063.


A Comprehensive Review of the Contribution of Mitochondrial DNA Mutations and Dysfunction in Polycystic Ovary Syndrome, Supported by Secondary Database Analysis.

Kobayashi H, Matsubara S, Yoshimoto C, Shigetomi H, Imanaka S Int J Mol Sci. 2025; 26(3).

PMID: 39940939 PMC: 11818232. DOI: 10.3390/ijms26031172.


Redefining Polycystic Ovary Syndrome: Transformative Diagnostic and Management Changes in the 2023 Guidelines.

Hong A Endocrinol Metab (Seoul). 2025; 40(1):64-66.

PMID: 39933433 PMC: 11898310. DOI: 10.3803/EnM.2024.2263.


References
1.
Unluhizarci K, Ozocak M, Tanriverdi F, Atmaca H, Kelestimur F . Investigation of hypothalamo-pituitary-gonadal axis and glucose intolerance among the first-degree female relatives of women with polycystic ovary syndrome. Fertil Steril. 2007; 87(6):1377-82. DOI: 10.1016/j.fertnstert.2006.11.075. View

2.
Clark A, Thornley B, Tomlinson L, Galletley C, Norman R . Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod. 1998; 13(6):1502-5. DOI: 10.1093/humrep/13.6.1502. View

3.
Crisosto N, Codner E, Maliqueo M, Echiburu B, Sanchez F, Cassorla F . Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 92(7):2739-43. DOI: 10.1210/jc.2007-0267. View

4.
Knochenhauer E, Key T, Kahsar-Miller M, Waggoner W, Boots L, Azziz R . Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83(9):3078-82. DOI: 10.1210/jcem.83.9.5090. View

5.
Yilmaz M, Bukan N, Ersoy R, Karakoc A, Yetkin I, Ayvaz G . Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod. 2005; 20(9):2414-20. DOI: 10.1093/humrep/dei070. View